Tissue Regenix Group PLC Potential Acquisition (6788F)
May 19 2017 - 6:36AM
UK Regulatory
TIDMTRX
RNS Number : 6788F
Tissue Regenix Group PLC
19 May 2017
Tissue Regenix Group plc
Potential Acquisition
Leeds, 19 May 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue
Regenix" or "The Group") the regenerative medical devices company,
notes the recent application for a temporary restraining order
("TRO") filed by one of the members of CellRight Technologies, LLC
("CellRight") with Bexar County District Court against CellRight, a
US regenerative medicine business based in San Antonio, Texas, in
relation to a potential sale of CellRight to Tissue Regenix. Tissue
Regenix confirms that it is in discussions with CellRight regarding
a possible acquisition of CellRight by Tissue Regenix.
There can be no certainty at this stage that the discussions
between the Group and CellRight will lead to an acquisition.
A further announcement will be made when appropriate.
This announcement contains inside information.
For more Information:
FTI Consulting Tel: 020
Brett Pollard/ Mo Noonan 3727 1000
========================================== ===========
Jefferies International Ltd Tel: 020
Simon Hardy / Harry Nicholas 7029 8000
Tissue Regenix Group Tel: 0330
Caitlin Pearson Corporate Communications 430 3073
Director
========================================== ===========
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human tissue leaving an acellular tissue scaffold
which is not rejected by the patient's body which can then be used
to repair diseased or worn out body parts. The potential
applications of this process are diverse and address many critical
clinical needs such as vascular disease, heart valve replacement
and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.', as
part of its commercialisation strategy for its dCELL(R) technology
platform.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQUKORRBRAVAAR
(END) Dow Jones Newswires
May 19, 2017 06:35 ET (10:35 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024